{"filings":[{"id":678237,"accession_number":"0001493152-26-025340","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2026-05-27T13:00:14+00:00","items":["5.07"],"status":"ready","headline":"Shuttle Pharma shareholders approve reverse stock split authorization up to 1:150 at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected with ~2.6M votes each; broker non-votes 582,364.","Ratification of Forvis Mazars as auditor approved 3,191,174 for, 12,417 against.","Say-on-pay advisory vote approved 2,650,932 for, 39,906 against.","Authorization for board to effect reverse stock split (1:2 to 1:150) approved 3,055,436 for, 119,431 against.","Meeting adjournment proposal also approved 3,077,059 for, though not needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95228,"accession_number":"0001493152-26-021767","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","2.01","3.02","3.03","5.02","5.03","9.01"],"status":"ready","headline":"Shuttle Pharma completes merger with United Dogecoin, pivots to crypto, raises $9.55M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger with United Dogecoin closed May 6; Shuttle issued 8,403 Series B-1 Preferred shares convertible at $1.24.","Closed $9.55M PIPE financing with Series B-2 Preferred and Common Warrants, convertible at $1.03.","Appointed Ryan Trasolini (ex-United Dogecoin CEO) as Co-Chief Executive Officer effective at closing.","Amended Asset Purchase Agreement: paid $3.65M cash, issued 270 Series B-1 shares; seller returned 320,496 common shares.","Director Oleh Nabyt resigned May 3 with no disagreement with management or board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95227,"accession_number":"0001493152-26-020830","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Shuttle Pharmaceuticals to acquire United Dogecoin, becomes public Dogecoin miner with $11M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration: 8,000 Series B-1 preferred shares convertible into ~32.3M common shares at $1.24 per share.","Concurrent $11M PIPE via Series B-2 convertible preferred and warrants; conversion price $1.03 per share.","United Dogecoin plans 3,000 ElphaPex mining rigs; targets 43,200 GH/s (~1.5% of global Dogecoin hash rate).","Ryan Trasolini (United Dogecoin CEO) to become co-CEO of combined company; closing expected May 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108135,"accession_number":"0001493152-26-009551","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Shuttle Pharmaceuticals prices $3.5M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3.5M from 2,238,800 shares and pre-funded warrants for 4,761,200 shares.","Pre-funded warrants exercisable at $0.001 per share with 4.99% beneficial ownership limitation.","Up to $1.5M of net proceeds allocated for marketing; remainder for working capital.","E.F. Hutton acted as placement agent; cash fee of 4.0% of gross proceeds plus expenses.","Offering closed March 9, 2026; registered on Form S-1 effective February 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108134,"accession_number":"0001493152-26-007204","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Shuttle Pharma prelim FY2025 net loss widens to ~$11-12M; G&A up 3.6x on investor ads","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary FY2025 net loss expected between $10.9M and $12.1M vs $9.1M in FY2024; revenue remains zero.","G&A expense surged to $5.2-5.8M from $1.4M, driven by $3.6M in investor relations advertising costs.","Working capital turns negative to deficit of $0.7-0.8M from positive $0.7M; cash used for Molecule.ai acquisition and trial wind-down.","Intangible assets of $9.8M from Molecule.ai acquisition; contingent consideration of $2.0M and consideration payable of $4.4M.","All convertible notes converted to stock; company needs additional financing to continue as going concern."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108133,"accession_number":"0001493152-26-004782","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Shuttle extends interim CEO Cooper's consulting agreement through August 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended consulting agreement with Number 2 Capital Corp. (owned by interim co-CEO Cooper) to August 1, 2026.","Monthly compensation unchanged at $20,000; 40-hour work week.","Amendment effective retroactively to September 11, 2025.","Agreement can be terminated by either party upon 30 days' notice.","Standard confidentiality and non-disclosure provisions included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108132,"accession_number":"0001493152-26-001861","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Shuttle Pharma appoints Yuying Liang as CFO; director Sachin Pathigoda resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yuying Liang, CPA, appointed CFO effective Jan 6, 2026; Chris Cooper remains interim CEO.","Liang's firm YLPC engages at $15,000/month for bookkeeping, accounting, and CFO services.","Director Sachin Pathigoda resigned Jan 8, 2026; resignation not due to any disagreement.","Liang concurrently serves as CFO of iSpecimen, BlockchainK2, Goldhills, and several other companies.","Board initiated process to fill Pathigoda's vacancy; successor to be appointed promptly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124554,"accession_number":"0001493152-25-029361","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Shuttle Pharma issues 19.99% stake (320,496 shares) in accelerated asset purchase payment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["First Amendment to Asset Purchase Agreement dated Dec 23, 2025 accelerates partial payment in stock.","Issued 320,496 shares of common stock at $1.76/share, representing 19.99% of outstanding shares.","Remaining First Installment Payment of $2,435,927.64 to be paid in cash only, per terms.","Amendment modifies definition of First Installment Payment and Purchase Price to reflect accelerated issuance.","Shares issued in unregistered transaction under Section 4(a)(2) and Rule 506(b)/Reg S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124553,"accession_number":"0001493152-25-025430","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Timothy Lorber resigns; Interim CEO Christopher Cooper assumes CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Lorber resigns as CFO effective Nov 21, 2025; will provide part-time transition through Dec 4, 2025.","Christopher Cooper (Interim CEO) appointed CFO effective Nov 21, 2025 while company searches for permanent CFO.","Lorber receives $20K retention bonus on Nov 21 and $10K on Dec 4; 39,854 unvested RSUs to vest on Feb 8, 2026.","RSU vesting includes 24,854 from Aug 8, 2025 grant, 14,620 from Aug 12, 2025 grant, and 380 from June 14, 2024 grant.","Separation Agreement includes mutual release, confidentiality, and non-disparagement provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124552,"accession_number":"0001493152-25-025082","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"Shuttle Pharma acquires AI drug discovery assets for up to $10M; $3M cash paid at close","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired substantially all assets of 1542770 BC Ltd. for total consideration up to $10M: $3M cash at close, $3M in 6 months, $2M in 1 year, plus up to $2M contingent milestone payments.","Seller may elect to receive future installments in cash or SHPH common stock, capped at 19.99% of outstanding shares without stockholder approval.","Milestone payments of $1M each require: (1) extension of AI platform for drug-target interaction within 3 months, (2) production of Agentic AI mode for automated drug discovery within 6 months.","Transaction closed November 20, 2025; Zhitian (Andy) Zhang remains as Key Consultant under non-compete and consulting agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124551,"accession_number":"0001493152-25-024618","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.01","1.02","2.05","9.01"],"status":"ready","headline":"Shuttle Pharma discontinues Ropidoxuridine trial, settles $557K debt for $300K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement with Theradex: $300K payment in full for ~$557K debt; both parties release claims.","Company discontinues clinical trials of Ropidoxuridine; ends enrollment and begins FDA-compliant winddown.","Additional ~$750K owed to five hospital research sites under separate agreements.","Expects majority of winddown costs in Q4 2025; amount still being assessed.","Interim CEO Christopher Cooper signs filing; trial termination follows Theradex's Oct 15 termination notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124550,"accession_number":"0001493152-25-023845","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Shuttle Pharmaceuticals regains compliance with Nasdaq equity requirement after $2.5M private placement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $1,394,161 on Sept 30, 2025, below Nasdaq's $2.5M minimum.","Company raised ~$2.5 million gross in a private placement on November 4, 2025.","Company believes it has regained compliance but Nasdaq will monitor ongoing compliance.","If next periodic report fails to show compliance, Company may be subject to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124549,"accession_number":"0001493152-25-021256","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Shuttle Pharmaceuticals raises $2.5M via private placement of pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-funded warrant for 625,156 shares at $0.001 exercise price, immediately exercisable.","Gross proceeds $2.5M; placement agent WestPark Capital paid 4% cash fee.","Closing on Nov 4, 2025; resale registration statement due within 15 days.","Beneficial ownership limited to 4.99% (can increase to 9.99% with 61 days notice)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124548,"accession_number":"0001493152-25-018788","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Shuttle Pharma signs $10M term sheet to buy Molecule assets; CRO Theradex terminates, seeks $1.09M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Binding term sheet for $10M purchase of substantially all assets and liabilities of Molecule; consideration in cash and stock per Shuttle's sole discretion, with milestones.","CRO Theradex terminated Master Agreement on Oct 15, 2025, demanding immediate payment of $1.091M; if unpaid in 30 days, services will cease.","Theradex is Shuttle's primary CRO; termination threatens clinical trial operations and requires immediate cash payment.","Transaction subject to due diligence, board approval, definitive agreements; exclusivity period of 90 days from Oct 20, 2025.","Shuttle intends to retain Molecule's CEO ZT Zhang for post-transaction transition and integration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141238,"accession_number":"0001493152-25-014489","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shuttle Pharma pays $1.45M to IR Agency for 2-month marketing services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consulting agreement with IR Agency LLC signed Sept 15, 2025; fee $1,450,000 for a 2-month term.","Services include creating company profiles, media distribution, and building a digital community.","Contract explicitly disclaims any guarantee of increased trading volume or stock price rise.","IR Agency acknowledges it carries no professional licenses and will not act as broker or advisor.","Company must indemnify IR Agency against claims arising from the advertising materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141237,"accession_number":"0001493152-25-014097","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Shuttle Pharma appoints Sachin Pathigoda and Angel Liriano as directors effective Sep 12, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Sachin Pathigoda as director and Chairman of Nominating & Corp Gov Committee; also on Audit Committee.","Appointed Angel Liriano as director and Chairman of Compensation Committee; also on Nominating & Corp Gov Committee.","Existing director George Scorsis appointed Chairman of the Audit Committee.","No family relationships or material interests disclosed for new directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141236,"accession_number":"0001493152-25-013890","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Joseph Tung resigns from Shuttle Pharmaceuticals board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Tung resigned as director on September 11, 2025.","Resignation was not due to any disagreement with the company.","No replacement has been announced.","Board size reduced; impact on governance unclear."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141235,"accession_number":"0001641172-25-026867","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Adam Chambers appointed to board of Shuttle Pharmaceuticals; principal of Bowery Consulting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective September 8, 2025; no family relationships with other directors/officers.","Chambers is principal of Bowery Consulting, lender under revolving loan (Feb 28, 2025) and consulting services (Mar 21, 2025).","No other material interests in transactions required to be disclosed under Item 404(a).","No arrangements or understandings under which he was appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141234,"accession_number":"0001641172-25-026719","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Steven Richards resigns from Shuttle Pharmaceuticals board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Richards resigned as director of Shuttle Pharmaceuticals Holdings, Inc. effective August 31, 2025.","Resignation stated to not be due to any disagreement with Company's operations, policies, or practices.","No replacement for Richards was announced; board size decreased accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141233,"accession_number":"0001641172-25-021566","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"President, COO and Secretary Peter Dritschilo resigns effective July 24, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Dritschilo resigned as President, Chief Operating Officer and Secretary on July 24, 2025.","No replacement has been named for the vacant positions.","Resignation effective immediately; Christopher Cooper remains Interim CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159036,"accession_number":"0001641172-25-016394","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Shuttle Pharma raises $4.25M in private placement of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.25M from sale of 21,924 shares and 1,158,953 pre-funded warrants at $3.60 per unit.","Pre-funded warrants exercisable immediately at $0.001 per share, expiring when fully exercised.","Net proceeds to be used for potential acquisitions, marketing, and general corporate purposes.","WestPark Capital acted as exclusive placement agent with a 4% fee of gross proceeds.","Company agreed to file resale registration statement within 10 days; lock-up on further issuances for up to 120 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159035,"accession_number":"0001641172-25-012536","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Shuttle Pharmaceuticals implements 70% salary reduction for all salaried employees, including named executive officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective May 21, 2025, all salaried employees and named executive officers face a 70% salary reduction.","Affected executives: Interim CEO Christopher Cooper, COO Peter Dritschilo, CSO Mira Jung, CCO Tyvin Rich, VP Regulatory Michael P. Vander Hoek.","CFO Timothy Lorber's 70% salary reduction is deferred and will be paid later, unlike the outright reduction for others.","The salary cuts reflect a significant cost-reduction measure amid apparent financial pressures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159034,"accession_number":"0001641172-25-010964","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"CSO and VP Regulatory resign; shareholders authorize reverse split and large issuances","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Anatoly Dritschilo resigned as CSO and director effective May 9, 2025; no disagreement cited.","Michael P. Vander Hoek resigned as VP Regulatory effective June 10, 2025; no disagreement cited.","Shareholders approved reverse stock split at ratio from 1-for-3 to 1-for-100.","Approved increase in equity plan shares by 5,000,000 and issuances of >19.99% stock on note conversion.","Approved issuances of >20% stock on convertible preferred offering and equity line of credit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159033,"accession_number":"0001641172-25-005553","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Shuttle Pharma to present at Planet MicroCap Showcase VEGAS 2025 on April 23","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Presentation by Dr. Anatoly Dritschilo on April 23 at 2:30 PM PT at Planet MicroCap Showcase VEGAS 2025.","Focus on Phase 2 trial update of Ropidoxuridine + RT for glioblastoma and Shuttle Diagnostics advancements for prostate cancer.","Company will also conduct 1x1 meetings on April 24 at the conference.","No financial results or material changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159032,"accession_number":"0001641172-25-003603","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Shuttle Pharma files provisional patent for PSMA-targeted PARP inhibitor conjugates for prostate cancer therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed provisional patent for PSMA-targeted PARP inhibitor conjugates, co-invented by Dr. Alan Kozikowski who contributed to Pylarify and Pluvicto.","Theranostic molecule aims to preferentially target prostate cancer cells, enhancing radiation and chemotherapy effects.","Global PSMA PET Imaging Market was $1.5B in 2022, expected to reach $2.0B by 2030; Pluvicto market predicted at $2B.","Shuttle Diagnostics subsidiary focuses on PSMA-B ligand and PC-Rad test for predicting RT outcomes in localized prostate cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159031,"accession_number":"0001641172-25-002757","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shuttle Pharma pays $2M to IR Agency for 3-month marketing services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered consulting agreement with IR Agency LLC to provide marketing and advertising services to the financial community.","Total fee of $2,000,000 due by April 5, 2025; non-refundable if client terminates during the 3-month term.","Consulting term is three months starting April 3, 2025; agreement may be extended by mutual consent.","Consultant makes no guarantee that the marketing will increase trading volume or share price of SHPH.","Company indemnifies consultant against claims arising from the advertising; client must approve materials before publication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177482,"accession_number":"0001641172-25-001880","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Shuttle Pharma appoints Christopher Cooper interim CEO; founder Dritschilio CSO & Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Cooper appointed interim CEO effective March 30, 2025.","Founder Dr. Anatoly Dritschilio becomes Chief Scientific Officer, remains Chairman of the Board.","Amended employment agreement: 3-year term, $274,000/year base salary, 12-month severance.","Dritschilio tasked with completing Phase 2 Ropidoxuridine glioblastoma trial by 2026, initiating Phase 3 by 2028.","Restructuring aims to add expertise in business and capital markets activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177481,"accession_number":"0001641172-25-000595","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shuttle Pharmaceuticals enters consulting deal with Bowery; $260K fee due after Nasdaq compliance regained","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six-month consulting agreement with Bowery Consulting Group effective March 21, 2025.","Services include research, due diligence, partnership evaluation, and capital raising strategy.","Total fee of $260,000, payable only after Shuttle regains full compliance with Nasdaq Listing Rules.","Agreement aims to support reaching milestones and attract investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177480,"accession_number":"0001493152-25-010211","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["1.01","3.01","7.01","9.01"],"status":"ready","headline":"Shuttle Pharma raises $5.75M in public offering, regains Nasdaq equity compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten offering of 1.34M shares and 17.8M pre-funded warrants at $0.30/share, net proceeds ~$5.2M.","Net proceeds to fund Phase II trial of Ropidoxuridine, $2.8M to CRO Theradex, plus up to $2.0M for marketing.","Believes it has regained compliance with Nasdaq minimum stockholders' equity rule of $2.5M after offering.","Offering was sole-underwritten by WestPark Capital; closed March 13, 2025.","Previously received Nasdaq deficiency notice on Sep 10, 2024; plan accepted Nov 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177479,"accession_number":"0001493152-25-009922","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Shuttle Pharma appoints Christopher Cooper as interim Co-CEO to boost business activities","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Cooper appointed interim Co-CEO effective March 11, 2025; focused on capital markets and business capabilities.","Dr. Anatoly Dritschilo continues as Chairman and Co-CEO overseeing scientific and clinical trial activities.","Consulting agreement with Cooper's entity pays $20,000/month for six months, 40 hours/week, with 30-day termination notice.","Cooper has 27 years of management/finance experience, raised over $100M in debt and equity for prior clients.","Company's ongoing Phase 2 trial of Ropidoxuridine for glioblastoma continues under Dritschilo's leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177478,"accession_number":"0001493152-25-008742","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["1.01","2.03","5.02","9.01"],"status":"ready","headline":"Shuttle Pharmaceuticals enters $2M revolving loan at 18%, replaces four directors with lender nominees","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving loan up to $2M from Bowery Consulting Group; 18% annual interest, 1-year maturity.","Proceeds for general corporate purposes, including financing a potential $6M public offering.","Four directors (Milton Brown, Bette Jacobs, Chris Senanayake, Joshua Schafer) resigned; three lender nominees appointed.","Events of default allow acceleration at 120% of outstanding principal plus interest and costs.","Financial advisor WestPark Capital received $20K fee and 4% fee on each draw."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177477,"accession_number":"0001493152-25-008462","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shuttle pays $75K to permanently waive Alto's right to $10M additional notes, warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $75,000 to Alto Opportunity Master Fund for permanent waiver of right to purchase up to $10M in additional notes and warrants.","Also granted one-time waiver of participation rights in Company's S-1 registered offering (filed Feb 13, 2025) if closed by March 31, 2025.","The $4.3M convertible note held by Alto is noted as satisfied in full.","Company and guarantors release Alto from all claims related to transaction documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177476,"accession_number":"0001493152-25-008306","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shuttle Pharma corporate update: Phase 2 glioblastoma trial 40% enrolled; no financial results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial of Ropidoxuridine for glioblastoma: 17 of 40 initial patients enrolled (40%), 8 completed all 7 cycles.","Trial conducted at Georgetown, Allegheny Health Network, UNC, UVA, Hackensack, Miami Cancer Institute.","Diagnostics subsidiary entered sponsored research agreement with UCSF to develop PSMA ligand as theranostic.","CEO Dr. Anatoly Dritschilo invested $237,500 along with other investors in recent financing.","Launched new corporate website highlighting dual approach to cancer therapeutics and diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177475,"accession_number":"0001493152-25-003985","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shuttle Pharma expands Phase 2 glioblastoma trial; adds sites, extends timeline through Jan 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Change Order with Theradex increases Phase 2 patients from 15 to 16 and sites from 4 to 6.","Total budget limited to $5,308,294; covers activities through 31 January 2026.","Protocol amendments versions 2.0 and 3.0 added; safety teleconferences expanded for medical monitor review.","Two sites (UNC and Georgetown) activated earlier than anticipated, driving budget increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177474,"accession_number":"0001493152-25-002945","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Shuttle Pharma reaches 25% enrollment in Phase 2 trial of Ropidoxuridine for glioblastoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial randomization targets 40 patients: 20 at 1,200 mg/day, 20 at 960 mg/day to identify optimal dose.","After optimal dose selected, 14 more patients will be enrolled for survival comparison vs. historical controls.","Trial focuses on IDH wild-type, methylation-negative glioblastoma; standard care is radiation only.","Ropidoxuridine previously received FDA Orphan Drug Designation; six major cancer centers are participating.","CEO Anatoly Dritschilo said enrollment is ahead of expectations; no results or guidance changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177473,"accession_number":"0001493152-25-001132","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Shuttle Pharma receives Nasdaq bid price deficiency notice; 180-day cure period until June 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter Dec 31, 2024 for failing to maintain minimum $1.00 bid price for 30 consecutive business days.","Has 180 calendar days until June 30, 2025 to regain compliance by closing bid price >= $1.00 for 10 consecutive business days.","If not compliant by June 30, may be eligible for additional 180-day period if meeting other listing standards and intending to cure via reverse stock split.","Listing continues under symbol SHPH; company considering available options to regain compliance.","CEO to participate in Lytham Partners fireside chat on Jan 13, 2025; plans to discuss Ropidoxuridine Phase 2 trial and Shuttle Diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194210,"accession_number":"0001493152-24-050700","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Shuttle Pharma enters $291K sponsored research agreement with UCSF for PSMA-B theranostic development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sponsored research agreement with UCSF, $291,607 cost, 1-year term, for preclinical PSMA-B ligand development.","UCSF will develop radiosynthetic methods for [18F]FPA-ACUPA probe and test binding in prostate cancer cell lines and mouse models.","Shuttle holds exclusive license to PSMA-B IP and has filed a patent application with USPTO.","PSMA-B ligand is a theranostic candidate for prostate cancer diagnosis and therapy, with market opportunities cited.","Pluvicto market predicted at $2B; PSMA PET imaging market expected to reach $2.0B by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194209,"accession_number":"0001493152-24-047747","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Shuttle Pharma doses first patient at UVA Cancer Center in Phase 2 glioblastoma trial of Ropidoxuridine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled and dosed at UVA Cancer Center; second site after Miami Cancer Institute.","Phase 2 trial: 40 patients randomized to 1,200 or 960 mg/day to determine optimal dose, then add 14 more.","Trial targets IDH wild-type, methylation negative glioblastoma; median survival <12 months with only radiation.","Ropidoxuridine has FDA Orphan Drug Designation for glioblastoma.","Six centers conducting trial: UVA, Georgetown, John Theurer, Allegheny Health, Miami Cancer Institute."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194208,"accession_number":"0001493152-24-045199","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shuttle Pharma doses first three patients in Phase 2 glioblastoma trial; raises $4.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma; screening for additional patients ongoing.","Paid off entire $4.3M Senior Secured Convertible Note ahead of March 2025 maturity.","Completed $4.5M public offering; proceeds to fund clinical trials and working capital.","Closed $790k convertible note/warrant offering, including $237.5k from CEO Anatoly Dritschilo.","Cash balance $4.1M as of October 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194207,"accession_number":"0001493152-24-043249","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Shuttle Pharma closes $4.5M public offering of stock and warrants for clinical trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.5M from 395,574 shares, 2.55M pre-funded warrants, 2.95M common warrants at $1.525/unit.","Proceeds primarily for IND-enabling and Phase I/II trials, including $2.3M to Theradex for Ropidoxuridine Phase II.","Common warrants exercisable at $1.40 per share, 5-year term; pre-funded warrants at $0.001 per share.","Placement agents A.G.P./Alliance Global Partners and Boustead Securities, with 9% aggregate cash fee.","Post-closing shares outstanding: 3,341,673 (excluding warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194206,"accession_number":"0001493152-24-042786","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Shuttle Pharma doses first three patients in Phase 2 trial of Ropidoxuridine for glioblastoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma.","Trial targets IDH wild-type, methylation-negative glioblastoma patients with no cure.","Initial 40 patients randomized to 1,200 mg/day or 960 mg/day; then add 14 on optimal dose.","Expected trial completion in 18-24 months.","Orphan Drug Designation from FDA provides potential 7-year exclusivity if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194205,"accession_number":"0001493152-24-042677","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Shuttle Pharma completes enrollment agreements for Phase 2 Ropidoxuridine glioblastoma trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six trial sites finalized: Georgetown, UNC, UVA, Hackensack, Allegheny Health Network, Miami Cancer Institute.","Patient screening underway; 40 patients randomized to 1,200 mg/day or 960 mg/day dose groups.","Optimal dose group will add 14 patients for survival comparison vs historical controls; trial completion in 18-24 months.","Ropidoxuridine holds FDA Orphan Drug Designation for glioblastoma, offering potential marketing exclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194204,"accession_number":"0001493152-24-042614","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CEO to present at ThinkEquity Conference; updates on Phase 2 glioblastoma trial and diagnostics","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Dr. Anatoly Dritschilo will present at ThinkEquity Conference on Oct 30, 2024 at 8:30am ET.","Presentation covers Phase 2 trial of Ropidoxuridine for glioblastoma; no new data disclosed.","Update on Shuttle Diagnostics subsidiary: predictive biomarkers for prostate cancer and PSMA ligand.","Company posted updated investor presentation on its website; one-on-one meetings available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194203,"accession_number":"0001493152-24-042462","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Shuttle Pharma closes second tranche of $1.3M note offering, total $790K raised","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second closing on Oct 21 added $220K net proceeds ($231,579 in Notes) from two accredited investors.","Investors received 88,544 warrants exercisable at $1.49/share (125% of prior closing price).","CEO Dr. Anatoly Dritschilo invested $237,500 in the first closing on Oct 14.","Total offering gross proceeds $790K; Notes carry 5% OID and are senior secured convertible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194202,"accession_number":"0001493152-24-041443","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Shuttle Pharma closes $600K convertible note offering; CEO invests $237.5K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $600,000 of an up to $1.3 million senior secured convertible note and warrant offering.","CEO Anatoly Dritschilo invested $237,500 in the offering.","Notes carry 5% OID, 14.5% interest, 1-year term, convertible at 110% premium; prepayable at 107%.","Warrants for 45% of conversion shares, exercisable at 125% of prior day's closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210535,"accession_number":"0001493152-24-036223","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Shuttle Pharma receives Nasdaq delisting notice for low equity ($801K vs $2.5M)","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Shuttle Pharma on Sept 10, 2024 of non-compliance with minimum stockholders' equity of $2.5M; reported equity $801,434.","Company has 45 days (until Oct 25, 2024) to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension.","Non-compliance has no immediate effect on listing; if plan rejected or not met, securities could be delisted with appeal rights.","Company is evaluating actions to regain compliance but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210534,"accession_number":"0001493152-24-035667","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shuttle Pharmaceuticals borrows $250k from CEO at 12% interest, repayable in 12 months","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $250,000 promissory note to CEO Anatoly Dritschilo on September 4, 2024.","Interest accrues at 12% per annum simple interest; principal and interest due in 12 equal monthly installments.","Final payment due September 4, 2025; default rate increases to 20%.","Loan proceeds provide working capital; CEO is the sole lender."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210533,"accession_number":"0001493152-24-034987","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Shuttle Pharma begins Phase 2 glioblastoma trial; regains Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial of Ropidoxuridine for glioblastoma opened at two sites; four more anticipated this month.","40 patients initially randomized to 1,200 mg/day or 960 mg/day; then 14 more on optimal dose.","FDA Orphan Drug Designation granted for Ropidoxuridine; potential marketing exclusivity.","Nasdaq non-compliance resolved after filing re-audited financials and delayed Q2 2023 10-Q.","Trial expected to complete in 18-24 months; primary endpoint survival vs historical controls."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210532,"accession_number":"0001493152-24-034124","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Shuttle Pharma regains Nasdaq minimum bid price compliance after trading above $1.00 for 10 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained compliance with Nasdaq Listing Rule 5550(a)(2) on August 27, 2024.","Traded above $1.00 per share for 10 consecutive trading days from August 13 to August 26, 2024.","Press release issued August 28, 2024 confirming Nasdaq notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210531,"accession_number":"0001493152-24-033876","cik":1757499,"company_name":"Shuttle Pharmaceuticals Holdings, Inc.","ticker":"SHPH","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Shuttle Pharma receives Nasdaq non-compliance notice for late Q2 10-Q filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified on Aug 21, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delayed Q2 10-Q.","Delay caused by re-audit of 2022 financials after SEC sanctions on former auditor B.F. Borgers CPA.","Company expects to file amended 10-K/A for 2023 and amended Q1 10-Q in days, then Q2 10-Q to regain compliance.","If more time needed, can submit compliance plan within 60 days for up to 180-day extension.","Nasdaq notice has no immediate effect on listing of SHPH common stock on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3541786.370334743,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-08-26T23:59:59+00:00|210531"}